Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
30
result(s) for
"Medical care European Union countries Marketing."
Sort by:
Healthcare
Emerging challenges related to socio-demographics and economics require new approaches for academics, politicians, hospital management, clinical staff, public institutions, and firms doing business in the healthcare industries.
This book provides valuable insights for understanding modern and complex healthcare market configurations in Europe.
Taking a unique cross-country perspective the authors figure out critical success factors for relevant stakeholders.
Mario Glowik is Professor of International Strategic Management at the Berlin School of Economics and Law. He holds a Doctorate in Business Administration from the Freie Universität Berlin in Germany and gained his habilitation (post-doctoral qualification) at the Vienna University of Economics and Business, Austria.
Slawomir Smyczek is Marketing Professor at the University of Economics in Katowice (Poland), where he earned his Ph.D. In 2010, the Polish Prime Minister awarded his habilitation thesis as the best in the field of economics in the entire country.
eBook
Brexit: Severe Risks to Britain’s National Health Service
A document purporting to set out its plan was a list of vague aspirations, lacking any recognition of the need to negotiate future arrangements with the remaining 27 EU member states and the European Parliament. Switzerland- a non-EU country with significant pharmaceutical manufacturing-typically waits six months before granting marketing authorization to new drugs introduced by the EMA and FDA.2 Manufacturers of some highly specialized drugs might also decide that the additional cost of obtaining regulatory approval in the relatively small UK market is not worth the cost and effort. [...]the United Kingdom's position in the European & Developing Countries Clinical Trials Partnership-which funds phase II and III clinical trials of new drugs, vaccines, or diagnostics that benefit developing countries-is uncertain.4 EU-WIDE REGULATIONS AFFECTING HEALTH The EU has implemented a large number of regulations addressing the broader determinants of health, in areas such as food safety, air and water quality, chemicals, health and safety, climate change, waste management, tobacco, and the quality and safety of human organs for transplantation, human tissue, and blood.5 These areas highlight the confusion and contradictions in what little is known about the government's intentions. Yet the UK prime minister has rejected either paying into the EU budget, except as a limited and temporary measure, or allowing the United Kingdom to be subject to the European Court ofJustice, the body established to resolve any disputes.
Journal Article
Can domestic medical tourism contribute to healthcare equity? A commentary
Pupose - This essay uses service marketing concept to discuss how domestic medical tourism (DMT) can contribute to healthcare equity in developed countries.
Approach - The authors take up several vital issues. First, the potential benefits of DMT are outlined from a healthcare equity perspective; second, the challenges that DMT confronts in reaching its aim are identified; and finally, a few research areas are suggested.
Finding - It is suggested that increased awareness about the healthcare service and proper service delivery are required to improve healthcare equity.
Practical implication - This paper raises several research issues from service marketing to deal with delivery, communication, efficiency, and insurance practices regarding healthcare.
Social implication - From a societal point of view, it explores how healthcare equity can be improved by DMT.
Journal Article
Improving access to HIV/AIDS medicines in Africa : trade-related aspects of intellectual property rights flexibilities
The study begins with an overview of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement and its flexibilities, delineating the legal requirements of the TRIPS agreement regarding their use. It then examines the challenges entailed in the beneficial interpretation and implementation of the TRIPS agreement at both the national and regional levels under the auspices of African Regional Intellectual Property Organization (ARIPO) and African Intellectual Property Organization (OAPI). The next section reviews the domestic antiretroviral (ARV) production experiences of Zimbabwe, Kenya, South Africa, and Ghana with an eye for evaluating the option of sustainable local production. The study is based on existing literature and on interaction with various key players and resource persons in government institutions, the private sector, and civil society groups, especially nongovernmental organizations (NGOs) at the national level. Information was gathered from officials of the regional patent institutions, OAPI and ARIPO, along with official documents of these institutions. International organizations involved in HIV/AIDS work in Sub-Saharan Africa (SSA) also provided input. The study was conducted under considerable time and logistical constraints, making it difficult to meet and interview all the persons that the authors wished to consult during travel across the African continent. Another limitation was the lack of an easily accessible database on ARVs and other HIV/AIDS medicines being used in Africa, their patent status, and their relative prices. National drug procurement bodies were often reluctant to divulge information on prices and quantities of medicines obtained.
eBook
Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals
Correa describes national legal practices with respect to protection of test data before the adoption of the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement. As many developing nations are unable to access drugs needed to fight disease outbreaks, public health officials and lawmakers are attempting to find ways to lower costs and promote information sharing.
Journal Article
Patient mobility in the European Union
Getting healthcare in another European country should be straightforward, but it often creates problems for both patients and healthcare systems
Journal Article